 SAN DIEGO, Oct. 12, 2021 PRNewswire -- Aethlon Medical, Inc. Nasdaq: AEMD, a company developing medical technology to treat cancer and life-threatening infectious disease, today announced the publication of a manuscript in the peer-reviewed journal Frontiers in Medicine describing two cases of critically ill COVID-19 patients treated with the Hemopurifier, Aethlons therapeutic blood filtration system. The publication, titled Removal of COVID-19 spike protein, whole virus, exosomes and exosomal microRNAs by the Hemopurifier lectin-affinity cartridge in critically Ill patients with COVID-19 infection, is available here: The publication documents two critically ill COVID-19 patients receiving a combined total of nine, six-hour Hemopurifier treatment sessions. 